Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Argen-X N.V. (Argenx). (8/9/18). "Press Release: Argenx to Present at 2018 Wedbush PacGrow Healthcare Conference". Breda & Ghent.

Organisations Organisation Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Group Argen-X (Argenx) (Group)
  Organisation 2 Wedbush PacGrow
  Group Wedbush (Group)
Products Product Wedbush PacGrow Healthcare Conference 2018
  Product 2 SIMPLE Antibody™ discovery platform
Index term Index term Argen-X–Wedbush: investor conference, 201808 supply service Argenx presents at Wedbush PacGrow Healthcare Conference in NYC
Persons Person Comijn, Joke (Argen-X 201704 Corp Communications Manager)
  Person 2 DelGiacco, Beth (Stern IR 201511)
     


argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the Company will present on Tuesday, August 14th at 1:20 p.m. ET at the 2018 Wedbush PacGrow Healthcare Conference in New York.

A live webcast of the presentation will be available on the Company’s website at www.argenx.com. A replay of the webcast will be available for 90 days following the presentation.


About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and the three antibody engineering technologies are designed to enable the expansion of the therapeutic index of the company’s product candidates.

www.argenx.com


For further information, please contact:

Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco, VP Investor Relations (US)
+1 518 424 4980
bdelgiacco@argenx.com

   
Record changed: 2018-08-23

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Argen-X (Argenx) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top